CN110981815A - 用于生产化合物的方法 - Google Patents

用于生产化合物的方法 Download PDF

Info

Publication number
CN110981815A
CN110981815A CN201911315571.3A CN201911315571A CN110981815A CN 110981815 A CN110981815 A CN 110981815A CN 201911315571 A CN201911315571 A CN 201911315571A CN 110981815 A CN110981815 A CN 110981815A
Authority
CN
China
Prior art keywords
formula
compound
reacting
reaction
xxix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911315571.3A
Other languages
English (en)
Chinese (zh)
Inventor
H.施尔默
P.鲁本鲍尔
B.凯尔
B.奥勒尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solvay SA
Original Assignee
Solvay SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay SA filed Critical Solvay SA
Publication of CN110981815A publication Critical patent/CN110981815A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201911315571.3A 2015-03-18 2016-03-15 用于生产化合物的方法 Pending CN110981815A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15159570 2015-03-18
EP15159570.9 2015-03-18
CN201680028214.7A CN107635972A (zh) 2015-03-18 2016-03-15 用于生产(4s)‑4‑[4‑氰基‑2‑(甲基磺酰基)苯基]‑3，6‑二甲基‑2‑氧代‑1‑[3‑(三氟甲基)苯基]‑1，2，3，4‑四氢嘧啶‑5‑甲腈的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680028214.7A Division CN107635972A (zh) 2015-03-18 2016-03-15 用于生产(4s)‑4‑[4‑氰基‑2‑(甲基磺酰基)苯基]‑3，6‑二甲基‑2‑氧代‑1‑[3‑(三氟甲基)苯基]‑1，2，3，4‑四氢嘧啶‑5‑甲腈的方法

Publications (1)

Publication Number Publication Date
CN110981815A true CN110981815A (zh) 2020-04-10

Family

ID=52684127

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911315571.3A Pending CN110981815A (zh) 2015-03-18 2016-03-15 用于生产化合物的方法
CN201680028214.7A Pending CN107635972A (zh) 2015-03-18 2016-03-15 用于生产(4s)‑4‑[4‑氰基‑2‑(甲基磺酰基)苯基]‑3，6‑二甲基‑2‑氧代‑1‑[3‑(三氟甲基)苯基]‑1，2，3，4‑四氢嘧啶‑5‑甲腈的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680028214.7A Pending CN107635972A (zh) 2015-03-18 2016-03-15 用于生产(4s)‑4‑[4‑氰基‑2‑(甲基磺酰基)苯基]‑3，6‑二甲基‑2‑氧代‑1‑[3‑(三氟甲基)苯基]‑1，2，3，4‑四氢嘧啶‑5‑甲腈的方法

Country Status (9)

Country Link
US (2) US10316001B2 (enExample)
EP (1) EP3271337B1 (enExample)
JP (4) JP7390100B2 (enExample)
KR (1) KR20170129191A (enExample)
CN (2) CN110981815A (enExample)
AU (1) AU2016232270B2 (enExample)
CA (1) CA2980071A1 (enExample)
ES (1) ES2877583T3 (enExample)
WO (1) WO2016146607A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112304919A (zh) * 2020-09-18 2021-02-02 厦门大学 一种乌头碱类植物毒素的定性定量检测方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7390100B2 (ja) 2015-03-18 2023-12-01 ピーエイチ・ファーマ・カンパニー・リミテッド （４ｓ）－４－［４－シアノ－２－（メチルスルホニル）フェニル］－３，６－ジメチル－２－オキソ－１－［３－（トリフルオロメチル）フェニル］－１，２，３，４－テトラヒドロピリミジン－５－カルボニトリルの製造方法
AU2019257632A1 (en) * 2018-04-24 2020-11-26 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
AU2020340281A1 (en) * 2019-08-23 2022-04-07 Ph Pharma Co., Ltd. Use of a neutrophil elastase inhibitor in lung disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903356A (zh) * 2007-12-20 2010-12-01 拜耳先灵制药股份公司 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214053D0 (en) 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
US6372936B1 (en) * 1999-06-09 2002-04-16 Eli Lilly And Company Optical resolution of aminoisobobutyric acid
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
WO2004024701A1 (en) 2002-09-10 2004-03-25 Bayer Healthcare Ag Heterocyclic derivatives
MXPA05002644A (es) 2002-09-10 2005-09-20 Bayer Healthcare Ag Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos.
GB0220962D0 (en) * 2002-09-10 2002-10-23 Bayer Ag Heterocyclic derivatives
AU2003290735A1 (en) 2002-12-06 2004-06-30 Eli Lilly And Company Inhibitors of monoamine uptake
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005082863A2 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
ES2394177T3 (es) 2004-02-26 2013-01-23 Bayer Intellectual Property Gmbh 1,4-diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0520743D0 (en) 2005-10-12 2005-11-23 Argenta Discovery Ltd Compounds and their use
MX2008007248A (es) * 2005-12-05 2008-09-03 Wyeth Corp Proceso para preparar derivados de cicloalcanol arilo sustituidos.
DE602007009095D1 (de) 2006-05-04 2010-10-21 Pulmagen Therapeutics Inflamma Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
US20100010024A1 (en) 2006-07-01 2010-01-14 Bayer Healthcare Ag Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102009016553A1 (de) 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung
JP7390100B2 (ja) 2015-03-18 2023-12-01 ピーエイチ・ファーマ・カンパニー・リミテッド （４ｓ）－４－［４－シアノ－２－（メチルスルホニル）フェニル］－３，６－ジメチル－２－オキソ－１－［３－（トリフルオロメチル）フェニル］－１，２，３，４－テトラヒドロピリミジン－５－カルボニトリルの製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903356A (zh) * 2007-12-20 2010-12-01 拜耳先灵制药股份公司 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VON NUSSBAUM, FRANZ: "Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases", 《CHEMMEDCHEM》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112304919A (zh) * 2020-09-18 2021-02-02 厦门大学 一种乌头碱类植物毒素的定性定量检测方法

Also Published As

Publication number Publication date
JP2021138711A (ja) 2021-09-16
US20190248750A1 (en) 2019-08-15
US10316001B2 (en) 2019-06-11
CA2980071A1 (en) 2016-09-22
KR20170129191A (ko) 2017-11-24
JP7125450B2 (ja) 2022-08-24
AU2016232270B2 (en) 2020-09-03
EP3271337B1 (de) 2021-03-03
WO2016146607A1 (de) 2016-09-22
AU2016232270A1 (en) 2017-10-19
JP2018508549A (ja) 2018-03-29
JP7117415B2 (ja) 2022-08-12
CN107635972A (zh) 2018-01-26
EP3271337A1 (de) 2018-01-24
JP2022145951A (ja) 2022-10-04
ES2877583T3 (es) 2021-11-17
US20180072685A1 (en) 2018-03-15
JP2020172529A (ja) 2020-10-22
US10676443B2 (en) 2020-06-09
JP7390100B2 (ja) 2023-12-01

Similar Documents

Publication Publication Date Title
JP7117415B2 (ja) （４ｓ）－４－［４－シアノ－２－（メチルスルホニル）フェニル］－３，６－ジメチル－２－オキソ－１－［３－（トリフルオロメチル）フェニル］－１，２，３，４－テトラヒドロピリミジン－５－カルボニトリルの製造方法
CN101643469B (zh) 一种盐酸巴尼地平的合成工艺
WO2021238963A1 (zh) 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
CN103435575A (zh) 1-（ 3-（ 3-（ 4-氯苯基）丙氧基）丙基）哌啶盐酸盐的制备方法
HK40019597A (en) Method for producing compounds
CN103626759B (zh) 一种阿哌沙班的中间体的制备方法
CN104080770A (zh) 用于制备罗氟司特的改进方法
US20080194825A1 (en) Process for obtaining montelukast
KR100990046B1 (ko) 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
CN103922999B (zh) 一种达比加群酯中间体的制备方法及中间体化合物
CN104892491B (zh) 一种合成帕罗西汀手性中间体的方法
KR101603324B1 (ko) 3-알킬티오-2-브로모피리딘 화합물의 제조방법
JP6231262B2 (ja) ピタバスタチンカルシウムの前駆体の製造法
JP2004528380A (ja) ゾルピデムの製造方法
CN104725294B (zh) 一种奥拉西坦关键中间体2-(2,4-二氧代吡咯烷-1-基)乙酸乙酯的合成新方法
KR102204267B1 (ko) 대체된 (r)-3-(4-메틸카바모일-3-플루오로페닐아미노)테트라하이드로퓨란-3-엔카르복실산(변이체) 및 이의 에스테르, 제조 방법 및 용도
CN109942511A (zh) 一种制备1,3-二（1,4-二氮杂环庚烷基）丙烷的方法
WO2012157504A1 (ja) β－ラクタム化合物およびその製造方法
JP2010189293A (ja) １，４―ジヒドロピリジン誘導体の製造法
KR101660874B1 (ko) 리네졸리드의 제조방법 및 그 중간체
CN121717751A (zh) 手性哌啶酮类化合物的制备方法
WO2008012974A1 (en) Novel imidazolidinone derivative, method of producing the same and method of producing optically active amino acid
CN101006043A (zh) 13－氧代三环[8.2.1.03.8]十三碳－3(8),4,6－三烯－5－羧酸酯的对映选择性合成
HK1099931A1 (zh) 苯并氧硫烷的合成方法和中间体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40019597

Country of ref document: HK